Teijin (3401) Investor Day 2025 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2025 summary
19 Dec, 2025Strategic focus and business positioning
Emphasizes a customer-centric business model leveraging expertise in fibers, healthcare, and resin to meet diverse needs, building strong relationships and trust.
Integrates fiber, home care, and healthcare services with resin and plastic business for new business creation.
Recent divestments and acquisitions sharpen focus on core areas: fiber, healthcare, and resin, transitioning to a growth phase.
Expanding fiber products through partnerships and acquisitions, and strengthening healthcare and resin businesses.
Focus on profitability and customer-centricity through portfolio strengthening and technology combinations.
Resin and plastic business overview
Over 60 years of history in polycarbonate resin, with global sales and R&D concentrated in Asia, especially China, Japan, and Thailand.
PC resins account for about 80% of revenues, with a diverse lineup including functional resins, compounds, and flame retardants.
Shifted from general-purpose to high-value-added products, stabilizing profits despite market volatility and competition.
Sales volume of high-value-added products has remained stable, even as general-purpose product sales declined.
Product strengths and quality
Maintains high quality and reliability, with strong customer relationships and technical centers in Japan, China, and ASEAN.
Proprietary manufacturing and special polymerization methods provide quality advantages over competitors, especially Chinese manufacturers.
Broad product lineup and expertise in blending compounds to meet specific customer requirements, including high market share in flame retardants.
Differentiates through rapid product development, quality stability, and rapid prototyping.
Latest events from Teijin
- Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation27 Feb 2026 - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 202623 Feb 2026 - Profit and revenue growth offset healthcare headwinds, with rare disease and home care focus.3401
Q3 202523 Dec 2025 - Major impairment and business transfer drive net loss; outlook cut, dividend steady.3401
Q2 20261 Dec 2025 - FY2024 saw profit recovery and portfolio transformation; higher FY2025 income expected.3401
Q4 202520 Nov 2025 - Profits and revenue fell in Q1 FY2025, but full-year outlook and dividend remain steady.3401
Q1 20265 Aug 2025 - Teijin accelerates healthcare growth with a focus on rare diseases, home care, and innovation.3401
Investor Update13 Jun 2025 - Q1 FY2024 revenue and profit surged, with IT business divestiture and IFRS adoption underway.3401
Q1 202513 Jun 2025 - Impairment losses offset strong 1H growth; asset sales and restructuring support FY2024 outlook.3401
Q2 202513 Jun 2025